📊 BGLC Key Takeaways
Is BioNexus Gene Lab Corp (BGLC) a Good Investment?
BioNexus Gene Lab Corp is a pre-revenue profitability stage company with severe operational challenges. Despite having modest revenue of $6.9M, the company is burning cash at an alarming rate (-$2.8M operating cash flow) with negative margins across all profitability measures (-28.1% net margin, -27.8% operating margin). The combination of persistent unprofitability, significant cash burn relative to asset base, and zero insider confidence signals acute fundamental distress.
BioNexus Gene Lab Corp shows weak fundamentals driven by low gross profitability, deeply negative operating and net margins, and significant free cash flow burn relative to revenue. While the balance sheet is clean with high liquidity, no meaningful leverage, and positive equity, the business currently lacks evidence of durable earnings power or efficient growth. Unless margins improve materially and operating cash burn narrows, the financial profile remains high risk.
Why Buy BioNexus Gene Lab Corp Stock? BGLC Key Strengths
- Strong liquidity position with 8.30x current ratio and $1.2M in cash reserves
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial distress risk
- Relatively low absolute liabilities at $805K provide some buffer
- Strong liquidity with an 8.30x current ratio and 6.81x quick ratio
- Debt-free balance sheet with minimal liabilities relative to equity
- Positive stockholders' equity of $6.82M provides balance sheet cushion
BGLC Stock Risks: BioNexus Gene Lab Corp Investment Risks
- Severe cash burn of $2.8M in operating activities against only $1.2M cash on hand creates acute solvency risk within 5-6 months
- Negative gross margin of 15.7% indicates fundamental business model problems with cost structure unsustainable at current revenue levels
- Consistently negative profitability across all metrics (ROA -25.6%, ROE -28.6%, net margin -28.1%) with zero evidence of operational improvement trajectory
- Negative free cash flow of -$2.8M and -40.8% FCF margin demonstrates the company is not operationally viable at present scale
- Zero insider Form 4 filings in last 90 days suggests complete lack of insider confidence or activity
- Gross margin of 15.7% is thin for supporting fixed costs, contributing to a -27.8% operating margin
- Operating cash flow of -$2.80M and free cash flow of -$2.84M indicate unsustainable cash burn without improvement
- Net losses and negative returns on equity and assets suggest weak growth quality and poor capital efficiency
Key Metrics to Watch
- Operating cash flow trajectory and monthly burn rate relative to cash reserves
- Gross margin improvement - critical indicator of cost structure viability
- Revenue growth rate and path to operating break-even
- Insider trading activity and capital raise announcements
- Gross margin and operating margin trend
- Operating cash flow burn relative to revenue
BioNexus Gene Lab Corp (BGLC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.30x current ratio provides a solid financial cushion.
BGLC Profit Margin, ROE & Profitability Analysis
BGLC vs Healthcare Sector: How BioNexus Gene Lab Corp Compares
How BioNexus Gene Lab Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioNexus Gene Lab Corp Stock Overvalued? BGLC Valuation Analysis 2026
Based on fundamental analysis, BioNexus Gene Lab Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioNexus Gene Lab Corp Balance Sheet: BGLC Debt, Cash & Liquidity
BGLC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioNexus Gene Lab Corp's revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
BGLC Revenue Growth, EPS Growth & YoY Performance
BGLC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | -$709.0K | $-0.40 |
| Q2 2025 | $2.0M | $95.3K | $0.05 |
| Q1 2025 | $2.1M | -$103.8K | $-0.01 |
| Q3 2024 | $2.6M | -$69.1K | N/A |
| Q2 2024 | $2.0M | -$69.1K | N/A |
| Q1 2024 | $2.4M | -$69.1K | N/A |
| Q2 2023 | $2.5M | $17.1K | N/A |
| Q1 2023 | $2.4M | $17.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioNexus Gene Lab Corp Dividends, Buybacks & Capital Allocation
BGLC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioNexus Gene Lab Corp (CIK: 0001737523)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BGLC
What is the AI rating for BGLC?
BioNexus Gene Lab Corp (BGLC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BGLC's key strengths?
Claude: Strong liquidity position with 8.30x current ratio and $1.2M in cash reserves. Minimal debt burden with 0.00x debt-to-equity ratio reducing financial distress risk. ChatGPT: Strong liquidity with an 8.30x current ratio and 6.81x quick ratio. Debt-free balance sheet with minimal liabilities relative to equity.
What are the risks of investing in BGLC?
Claude: Severe cash burn of $2.8M in operating activities against only $1.2M cash on hand creates acute solvency risk within 5-6 months. Negative gross margin of 15.7% indicates fundamental business model problems with cost structure unsustainable at current revenue levels. ChatGPT: Gross margin of 15.7% is thin for supporting fixed costs, contributing to a -27.8% operating margin. Operating cash flow of -$2.80M and free cash flow of -$2.84M indicate unsustainable cash burn without improvement.
What is BGLC's revenue and growth?
BioNexus Gene Lab Corp reported revenue of $6.9M.
Does BGLC pay dividends?
BioNexus Gene Lab Corp does not currently pay dividends.
Where can I find BGLC SEC filings?
Official SEC filings for BioNexus Gene Lab Corp (CIK: 0001737523) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BGLC's EPS?
BioNexus Gene Lab Corp has a diluted EPS of $-1.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BGLC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioNexus Gene Lab Corp has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BGLC stock overvalued or undervalued?
Valuation metrics for BGLC: ROE of -28.6% (sector avg: 15%), net margin of -28.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BGLC stock in 2026?
Our dual AI analysis gives BioNexus Gene Lab Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BGLC's free cash flow?
BioNexus Gene Lab Corp's operating cash flow is $-2.8M, with capital expenditures of $36.0K. FCF margin is -40.8%.
How does BGLC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -28.1% (avg: 12%), ROE -28.6% (avg: 15%), current ratio 8.30 (avg: 2).